PBS-listed progesterone pessary slashes preterm birth risk
Monday, 31 May, 2021
A vaginal progesterone pessary is reported to be the first progesterone treatment to be reimbursed via the (PBS) for the prevention of preterm birth, following research demonstrating that vaginal progesterone can decrease the risk of preterm birth at <34 weeks by 49% and neonatal death by 69%.
Preterm births are the leading cause of death in children under five, with one in 11 babies born prematurely in Australia. It is well established that the earlier a baby is born, the more likely it is to experience complicated medical problems requiring special care in a neonatal intensive care unit (NICU). Health complications relating to preterm birth include jaundice, breathing difficulties, deafness, blindness, cerebral palsy, and lifelong intellectual and developmental disability.
鈥 for use in singleton pregnancies which are at risk due to a shortened cervix (mid-trimester sonographic cervix 鈮25 mm) and/or where there is a history of spontaneous preterm birth 鈥 are set to be reimbursed on the PBS from 1 June, covering the period from 16 weeks鈥 gestation to the time of birth.
Dr Chris Lehner, Consultant Obstetrician and Obstetric Co-Lead at the , said healthcare professionals will welcome access to effective solutions that reduce the risk of preterm birth.
鈥淏etter access to effective options that prevent preterm birth are very welcome. The reality is that one in 11 babies is still born premature in Australia, so it continues to be an important issue,鈥 Dr Lehner said. 鈥淭hose of us that care for pregnant women at risk of preterm births know how important it is to be able to suggest effective preventive options.鈥
General Manager Leanne Brydon said the company was very proud that its efforts to make Oripro more accessible had been successful.
鈥淭he PBS listing for Oripro means that not only pregnant women will have access to Australian-made, government-subsidised vaginal progesterone, but also that the Australian Government supports Australian pharmaceutical manufacturing and local jobs. It鈥檚 an exciting milestone for Perrigo.鈥
The product information can be accessed .
PBS information is available .
Victoria's Q3 median ED wait times the lowest on record
Victoria's quarter three performance data (January–March) has shown improvement across...
Irregularities in a clinician's cases prompt 15-month lookback
St Vincent's 黑料吃瓜群网 Sydney has detailed a 15-month lookback review — prompted by...
Two researchers receive $899,000 in cardiovascular funding
In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...